Precision BioSciences is rejigging its senior leadership team, putting Jeff Smith, Ph.D., in charge of its research programs and asking Chief Scientific Officer Derek Jantz, Ph.D., to focus on “formulating company strategy and managing relationships with external stakeholders.”

Though expectant mothers are closely monitored throughout the entire labor process, it’s still difficult to predict with absolute certainty how a birth will go, since there’s a wide variety of issues that can unexpectedly crop up during labor, throwing the entire process off course and potentially causing major complications.

Patients with Down syndrome face a lifetime of sensory, reproductive and intellectual disabilities that worsen with age. But despite affecting as many as 1 in 700 births, according to the Centers for Disease Control and Prevention, the mechanism behind the condition’s pathologies is poorly understood, and there are few effective treatments.

Three therapeutics for Alzheimer’s disease steal the headlines at the moment: Eisai and Biogen’s lecanemab, Genentech’s gantenerumab and Eli Lilly’s donanemab.

As Medtronic continues to await FDA clearance of the latest iteration of its MiniMed insulin pump, the medtech giant has churned out a steady stream of data supporting the device’s ability to improve outcomes for Type 1 diabetes patients.

Fresh off reporting promising results from a phase 3 study of its constipation relief device, Vibrant Gastro is keeping things moving.

AnaptysBio’s stuttering effort to rebuild its pipeline around imsidolimab has hit another setback. After flopping in palmoplantar pustulosis and acne, the anti-IL-36 receptor antagonist has failed to move the needle in the chronic skin disease hidradenitis suppurativa, leading the biotech to stop work on one indication and plan to out-license the asset.

Mereo BioPharma, under pressure from an activist investor, has reduced its head count to stretch its cash runway out into the second quarter of 2025. The biotech disclosed the cuts in a rebuttal to Rubric Capital Management’s “low-risk strategy” for unlocking the value of its assets while preserving cash.

Long gone are the days when hospital-grade vital sign monitoring required carts full of equipment, all attached to patients using a tangle of wires, sensors and probes. Now, compact and wireless wearable devices can churn out just as many measurements—if not more—on a constant basis, including body temperature, heart and respiratory rate, infection-related symptoms and more.

Despite the hype around adoptive T-cell therapies, it’s still a challenge to find therapeutic targets that are consistent across tumor types and aren’t expressed in healthy cells. Now, a team of scientists from the University of Pennsylvania working with immunotherapy drug development biotech Immatics has identified an antigen component that checks both of those boxes.